McKesson/$MCK

13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX

About McKesson

McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Ticker

$MCK

Primary listing

NYSE

Industry

Health Care Providers & Services

Employees

44,000

ISIN

US58155Q1031

McKesson Metrics

BasicAdvanced
$90B
28.03
$25.72
0.52
$2.75
0.39%

What the Analysts think about McKesson

Analyst ratings (Buy, Hold, Sell) for McKesson stock.

Bulls say / Bears say

McKesson raised its annual profit forecast, driven by strong demand for specialty medicines, indicating robust growth in high-margin segments. (Reuters)
The company completed the divestiture of its Canada-based Rexall and Well.ca businesses, allowing it to focus on expanding its oncology and biopharma growth platforms. (StockTitan)
Analysts have raised McKesson's price targets, with Bank of America increasing it to $755, reflecting confidence in the company's growth trajectory. (Techdows News)
McKesson forecasted second-quarter profit below Wall Street estimates, leading to a 9% drop in shares, indicating potential challenges in meeting earnings expectations. (TradingView News)
The company reported negative free cash flow of $1.5 billion in Q3 2024, partly due to onboarding new customers, which may raise concerns about cash management. (Panabee)
McKesson's Medical-Surgical segment experienced a 15% decline in adjusted operating profit, attributed to lower volumes and shifts in customer/product mix, potentially impacting overall profitability. (Panabee)
Data summarised monthly by Lightyear AI. Last updated on 21 Jun 2025.

McKesson Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

McKesson Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MCK

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs